Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announces its planned regulatory ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Chardan Capital Markets Raises Price Target on Amicus Therapeutics (FOLD); Reiterates Buy November 29, 2016 8:31 AM Leerink Partners Cuts Price Target on Amicus Therapeutics (FOLD) Following FDA Feedback November 29, 2016 7:59 AM Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry DiseaseNovember 28, 2016 4:09 PM